GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Net Income From Continuing Operations

Oculis Holding AG (FRA:CR5) Net Income From Continuing Operations : €-61.24 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Oculis Holding AG's net income from continuing operations for the three months ended in Mar. 2024 was €-16.63 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was €-61.24 Mil.

Oculis Holding AG Net Income From Continuing Operations Historical Data

The historical data trend for Oculis Holding AG's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Net Income From Continuing Operations Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
-13.69 -17.80 -39.16 -94.05

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.31 -13.09 -18.26 -13.27 -16.63

Oculis Holding AG Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-61.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oculis Holding AG (FRA:CR5) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Net Income From Continuing Operations
Comparable Companies
LXRX MGNX ICVX SPRY CHRS TERN AURA ERAS NAUT MLYS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
OCS:USA OCS:Iceland
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Website
https://www.oculis.com
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines